Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Nika Pharmaceuticals Q2 FY26 net loss widens to $19,694

Nika Pharmaceuticals Q2 FY26 net loss widens to $19,694

ReutersReuters2026/08/10 17:40
  • Nika Pharmaceuticals posted a net loss of USD 19,694 for the quarter ended June 30, 2026, widening from USD 18,381 a year earlier.
  • General and administrative expenses edged up to USD 14,848 from USD 14,300, while professional fees rose to USD 4,846 from USD 4,081.
  • Net cash used in operating activities narrowed to USD 20,957 for the six months ended June 30, 2026, versus USD 31,467 a year earlier.
  • Related-party loan proceeds fell to USD 22,000 from USD 45,000, with the company reporting no revenue and reliance on non-interest-bearing loans.
  • Management cited a timing shift in prepaid-expense amortization, adding about USD 7,820 to second-quarter expenses that otherwise would have been recorded in Q1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nika Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001826466-26-000049), on August 10, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!